Managing the risk of drug-induced liver injury

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 6, 2013, Pages 629-631

  Watkins, P B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CYTOCHROME P450 2C9;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOOD EXAMINATION; DRUG APPROVAL; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; JAUNDICE; LIVER FAILURE; LIVER INJURY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK MANAGEMENT; SIDE EFFECT; TOXIC HEPATITIS;

ARYL HYDROCARBON HYDROXYLASES; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 84887962686     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.182     Document Type: Review

References (11)

1. Watkins, P.B. Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther. 89, 788-790 (2011).
2. Rubin, L.J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002). (Pubitemid 34984638)
3. Channick, R.N. et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet 358, 1119-1123 (2001). (Pubitemid 32971843)
4. Actelion Pharmaceuticals. Briefing document concerning Tracleer (bosentan) in pulmonary arterial hypertensionhttp://www.fda.gov/ohrms/dockets/ ac/01/briefing/3775b2-09-Tracleer%20Briefing%20Book(red).pdf (6 July 2001).
5. Segal, E.S. et al. Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf. 28, 971-980 (2005). (Pubitemid 41483704)
6. Markova, S.M. et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clin. Pharmacol. Ther. 94, 678-686 (2013).
7. Singer, J.B. et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42, 711-714 (2010).
8. Spraggs, C.F. et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667-673 (2011).
9. Daly, A.K. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52, 21-35 (2012).
10. US Food and Drug Administration. Guidance for industry. Clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM337169.pdf (January 2013).
11. Drug-Induced Liver Injury Network. Ancillary studies.https://dilin.dcri. duke.edu/forresearchers/ancillary-studies>